Sign In
Buy APLT
$0.0959
+0 (+0%)
At Close: Apr 28, 2026
Analyzing Cartesian Therapeutics (NASDAQ:RNAC) and Applied Therapeutics (NASDAQ:APLT)
01:39am, Thursday, 19'th Feb 2026
Applied Therapeutics (NASDAQ: APLT - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get Free Report) are both small-cap medical companies, but which is the better investment? We will cont
Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics
08:39am, Tuesday, 03'rd Feb 2026
CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ:
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
08:00am, Friday, 30'th Jan 2026
CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly
Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension
08:15am, Thursday, 29'th Jan 2026
NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company” or “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformat
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
08:00am, Thursday, 29'th Jan 2026
CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly
Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer
08:56am, Wednesday, 28'th Jan 2026
CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly
Applied Therapeutics Inc. (NASDAQ:APLT) Short Interest Update
03:52am, Wednesday, 14'th Jan 2026
Applied Therapeutics Inc. (NASDAQ: APLT - Get Free Report) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 6,6
Here's Why Applied Therapeutics (APLT) Is a Great 'Buy the Bottom' Stock Now
10:56am, Tuesday, 16'th Dec 2025
Applied Therapeutics (APLT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions cou
APLT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Applied Therapeutics, Inc. is Fair to Shareholders
06:54am, Friday, 12'th Dec 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Therapeutics, Inc. (NASDAQ: APLT) to Cycle Group Holdings Limited for $0.088 per
Cycle Pharmaceuticals to Acquire Applied Therapeutics
05:25pm, Thursday, 11'th Dec 2025
Applied Therapeutic's lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases Applied Therapeutic's lea
Applied Therapeutics (APLT) Upgraded to Buy: Here's Why
01:01pm, Thursday, 27'th Nov 2025
Applied Therapeutics (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Applied Therapeutics Announces Corporate Updates
07:00am, Thursday, 20'th Nov 2025
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments fo
Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain
01:05pm, Thursday, 13'th Nov 2025
Applied Therapeutics, Inc. (NASDAQ: APLT) stock is trading lower on Thursday, with a session volume of 20.07 million, compared to its average volume of 4.88 million, according to Benzinga Pro.
Applied Therapeutics Reports Third Quarter 2025 Financial Results
07:00am, Thursday, 13'th Nov 2025
– Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes – Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat f
Halper Sadeh LLC Encourages Applied Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
10:25am, Tuesday, 28'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Applied Therapeutics, Inc. (NASDAQ: APLT) breached their fiduciary
